Q2 25 EPS
$2.97
BEAT +2.14%
Est. $2.91
Q2 25 Revenue
$15.42B
BEAT +2.61%
Est. $15.03B
vs S&P Since Q2 25
-6.7%
TRAILING MARKET
ABBV +7.3% vs S&P +14.0%
Market Reaction
Did ABBV Beat Earnings? Q2 2025 Results
AbbVie posted a confident second quarter for 2025, with adjusted diluted EPS of $2.97 edging past the $2.91 consensus by 2.14% and revenues of $15.42 billion climbing 6.7% year-over-year to clear analyst estimates by 2.61%, as the company's next-gene… Read more AbbVie posted a confident second quarter for 2025, with adjusted diluted EPS of $2.97 edging past the $2.91 consensus by 2.14% and revenues of $15.42 billion climbing 6.7% year-over-year to clear analyst estimates by 2.61%, as the company's next-generation immunology franchise continued to carry the growth story. Skyrizi was the headline performer, surging 62.2% to $4.42 billion, while Rinvoq added 41.8% to reach $2.03 billion, collectively absorbing the ongoing biosimilar pressure on Humira, whose revenues fell 58.1% to $1.18 billion. Neuroscience added further momentum, with the migraine portfolio delivering outsized contributions from Ubrelvy and Qulipta. GAAP earnings were weighed by $2.79 billion in contingent consideration fair-value adjustments, a dynamic that has drawn scrutiny across the broader pharma sector as deal-related accounting headwinds continue to cloud reported results for large-cap names. Looking ahead, AbbVie raised its full-year 2025 adjusted diluted EPS guidance to $11.88 to $12.08, up from $11.67 to $11.87, signaling sustained confidence in its immunology-led growth trajectory.
Key Takeaways
- • Skyrizi revenue growth of 62.2% year-over-year
- • Rinvoq revenue growth of 41.8% year-over-year
- • Neuroscience portfolio growth of 24.2% led by migraine therapies Ubrelvy and Qulipta
- • Adjusted operating margin of 44.3%
- • Lower adjusted tax rate of 16.2% vs 18.8% in prior year
ABBV YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
ABBV Revenue by Segment
With YoY comparisons, source: SEC Filings
ABBV Revenue by Geography
With YoY comparisons, source: SEC Filings
“AbbVie delivered another outstanding quarter with strong performance from our diversified growth platform. We also made meaningful pipeline progress with several regulatory approvals, encouraging clinical data and strategic investments in promising external innovation.”
— Robert A. Michael, Q2 2025 Earnings Press Release
ABBV Earnings Trends
ABBV vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABBV EPS Trend
Earnings per share: estimate vs actual
ABBV Revenue Trend
Quarterly revenue: estimate vs actual
ABBV Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.65 | — | $15.00B | +1.93% |
| Q4 25 MISS FY | $3.35 | $2.71 | -19.10% | $16.62B | +1.22% |
| FY Full Year | $9.94 | $10.00 | +0.64% | $61.16B | +0.33% |
| Q3 25 BEAT | $1.78 | $1.86 | +4.23% | $15.78B | +1.23% |
| Q2 25 BEAT | $2.91 | $2.97 | +2.14% | $15.42B | +2.61% |
| Q1 25 BEAT | $2.40 | $2.46 | +2.62% | $13.34B | +3.27% |